Participated · Series B · Sep 2025

Mercy BioAnalytics develops extracellular vesicle–based liquid biopsy tests aimed at the early detection of cancer. Its patented Mercy Halo platform uses biomarker co-localization to interrogate abundant blood-based extracellular vesicles that carry cancer signatures from their cell of origin. The company’s initial focus is the early detection of ovarian and lung cancers, and its blood-based ovarian cancer test portfolio is designed to detect pre-clinical high grade serous ovarian carcinoma in post-menopausal women. Mercy says the Mercy Halo ovarian cancer screening test shows unprecedented sensitivity and specificity in a blinded evaluation of samples from a randomized controlled trial. The company plans to commercialize its ovarian cancer tests and expand the Mercy Halo portfolio to include multi-cancer and lung cancer screening tests. Mercy is based in Waltham, Mass., and recently closed a financing to support commercialization and portfolio expansion. Mercy BioAnalytics is advancing the Mercy Halo extracellular vesicle‑based liquid biopsy platform to enable early detection of cancer. Mercy Halo seeks high clinical sensitivity and specificity by simultaneously detecting multiple cancer‑related biomarkers co‑localized on individual tumor‑derived extracellular vesicles. The test can be run on a very small volume of serum or plasma and uses a simple PCR‑based readout. The company closed an oversubscribed $41 million Series A to advance development and commercialization, with an initial focus on high‑risk lung cancer screening. Proceeds will also support clinical programs in ovarian cancer and the development of a broader portfolio of early‑detection tests. Preliminary data presented at ASCO, AACR and EDCC demonstrated promising performance for detecting Stage I and II lung and ovarian cancers, and Mercy is planning larger independent validation studies.

Participated · Series A · Jul 2024

Novocuff develops the Novocuff Cervical Control System (CCS), a medical device designed to stabilize and close the cervix to retain amniotic fluid and sustain cervical length with the goal of extending pregnancy. The company is focused on improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening. Novocuff says it aims to transform the standard of care and bring the device to global markets, including low- and middle-income countries. Proceeds from an oversubscribed $26 million Series A will fund team expansion, a U.S. multi-center pivotal clinical trial planned for early 2025, pursuit of marketing authorization, and early-stage commercialization. The company completed an initial $2 million seed round prior to the Series A and has added clinical hires Kathryn Wine (VP, Clinical Affairs) and Marissa VanDeVeer (Clinical Engineer). Novocuff frames its work against the global burden of preterm birth, citing WHO data that preterm complications caused roughly 1 million infant deaths in 2020.

Participated · Series A · Jun 2024

Axena Health develops the Leva® Pelvic Health System, an FDA‑cleared, prescription at‑home device that uses a vaginal motion sensor and integrated software to visualize pelvic movement and support pelvic floor muscle training. The Leva System is positioned as a non-invasive, medication‑free first-line treatment for urinary incontinence (UI) and chronic fecal incontinence (FI) and is supported by multiple clinical trials and published data, including studies in Obstetrics and Gynecology. Proceeds from the recent fundraise will support Axena’s continued U.S. commercial launch, where the company reports rising prescriber adoption and expanding payer coverage, and will accelerate work to scale treatments in low- and middle-income countries, including efforts in sub‑Saharan Africa. The system enables physician involvement, progress tracking, and remote monitoring to improve patient outcomes. Axena cites U.S. prevalence figures of over 78 million women affected by UI and 12 million by FI. The company is based in Newton, Massachusetts. Axena Health commercializes the Leva® Pelvic Health System, a prescription digital therapeutic that guides pelvic floor muscle training for urinary incontinence (UI) and chronic fecal incontinence (FI). The Leva System pairs a small FDA-cleared vaginal motion sensor with a smartphone app to provide real-time visualization, progress tracking, and physician involvement. Treatment is non-invasive, drug-free, performed at home in about five minutes per day, and is FDA-cleared for stress, mixed and mild-to-moderate urgency UI and first-line treatment of chronic FI in women. Axena highlights multiple clinical trials and peer-reviewed publications supporting Leva’s efficacy, including studies in Obstetrics and Gynecology (The Green Journal). The company is women-founded, women-funded and women-focused and describes itself as a newly-formed commercial-stage business based in Newton, Mass. The firm cites the large addressable need—affecting over 78 million and 12 million women in the U.S. for UI and FI respectively—and is positioning Leva as an accessible, scalable prescription treatment.

Participated · Series B · May 2024

May Health is a medical device company focused on expanding therapeutic options for women suffering from polycystic ovary syndrome (PCOS)-related infertility. Its lead product, the Anavi™ System, enables a one-time, office-based procedure intended to restore ovulation in patients who do not respond to, are contraindicated to, or decline first-line treatments. The device secured CE Mark certification under EU MDR in October 2025 and is currently being evaluated in the U.S. REBALANCE pivotal IDE trial across more than 15 fertility centers. By targeting a condition that affects an estimated 10–13% of reproductive-age women worldwide, the company addresses a significant unmet clinical need. Management is advancing toward FDA marketing authorization while simultaneously preparing for commercialization in Europe and the United States. Backed by a syndicate of life-science investors, May Health is capitalizing on strategic partnerships to accelerate clinical development and future market launch.

Participated · Series B · Apr 2024

Headquartered in Palo Alto, Midi Health operates a nationwide virtual clinic that addresses gaps in women’s healthcare from perimenopause and menopause to broader chronic and preventive needs. The company’s proprietary AI engine analyzes patient charts to personalize diagnosis, streamline scheduling and documentation, and continuously refine clinical protocols using one of the industry’s largest women’s-health datasets. Midi currently has insurance contracts that give more than 45 million U.S. women in-network access to its services, and over 25,000 patients seek care on the platform each week. Outcomes data show a 28-percentage-point increase in breast-cancer screening adherence, an 11-point rise in colorectal screening adherence, and up to a 13 percent reduction in total cost of care, alongside clinically significant reductions in A1c and LDL levels. The business complements its clinical model with an expanding specialist roster covering OB-GYN, cardiology, endocrinology, mood disorders, dermatology, longevity, and more. Recent executive hires from Tesla, Google, Meta, Lyft, and Omada Health signal a push to scale operations and brand awareness. Following its latest financing, Midi is valued at more than $1 billion and plans to broaden its AI capabilities and extend comprehensive women’s care across every life stage.